Your browser is no longer supported. Please, upgrade your browser.
Settings
OSMT Osmotica Pharmaceuticals plc daily Stock Chart
OSMT [NASD]
Osmotica Pharmaceuticals plc
Index- P/E- EPS (ttm)-9.15 Insider Own- Shs Outstand52.19M Perf Week24.78%
Market Cap365.33M Forward P/E- EPS next Y-1.03 Insider Trans- Shs Float13.62M Perf Month-5.66%
Income-350.10M PEG- EPS next Q-0.16 Inst Own38.40% Short Float6.88% Perf Quarter69.90%
Sales245.80M P/S1.49 EPS this Y-151.70% Inst Trans-0.01% Short Ratio3.06 Perf Half Y110.84%
Book/sh2.70 P/B2.59 EPS next Y78.30% ROA-37.00% Target Price8.25 Perf Year-8.26%
Cash/sh1.88 P/C3.73 EPS next 5Y- ROE-85.80% 52W Range2.20 - 8.28 Perf YTD0.14%
Dividend- P/FCF14.00 EPS past 5Y- ROI-13.60% 52W High-15.46% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin49.10% 52W Low218.18% ATR0.51
Employees466 Current Ratio2.10 Sales Q/Q-1.20% Oper. Margin- RSI (14)62.72 Volatility9.23% 8.09%
OptionableNo Debt/Eq1.89 EPS Q/Q- Profit Margin- Rel Volume1.73 Prev Close6.79
ShortableYes LT Debt/Eq1.89 EarningsFeb 13 AMC Payout- Avg Volume305.48K Price7.00
Recom1.70 SMA2014.84% SMA5014.15% SMA20068.34% Volume527,244 Change3.09%
Jun-11-19Initiated Barclays Overweight $11
Nov-12-18Initiated Wells Fargo Outperform
Nov-12-18Initiated RBC Capital Mkts Outperform $17
Nov-12-18Initiated Jefferies Buy $21
Jan-18-20 05:09PM  Notable Insider Buys Last Week: Small-Cap Biotechs Benzinga
Jan-16-20 07:22AM  The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga +12.65%
Jan-08-20 08:40PM  Osmotica Announces Pricing of Public Offering of Ordinary Shares GlobeNewswire -5.27%
Jan-06-20 06:50AM  Osmotica Announces Proposed Public Offering of Ordinary Shares GlobeNewswire -16.48%
Dec-23-19 11:40AM  OSMT or ILMN: Which Is the Better Value Stock Right Now? Zacks
Dec-10-19 11:50AM  Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now? Zacks +14.41%
Dec-06-19 11:40AM  OSMT vs. QGEN: Which Stock Should Value Investors Buy Now? Zacks
Nov-30-19 11:38AM  Did Hedge Funds Drop The Ball On Osmotica Pharmaceuticals plc (OSMT) ? Insider Monkey
Nov-27-19 07:44AM  Moving Average Crossover Alert: Osmotica Pharmaceuticals Zacks
Nov-25-19 06:09AM  Buy These 6 Best Value Stocks to Make the Most of P/B Ratio Zacks +8.58%
Nov-22-19 09:48AM  The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical Zacks +15.65%
Nov-21-19 12:15PM  Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD Zacks
09:10AM  Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now? Zacks
Nov-20-19 09:30AM  OSMT or QGEN: Which Is the Better Value Stock Right Now? Zacks
06:50AM  Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis (Droopy Eyelid) GlobeNewswire
Nov-18-19 08:49AM  Earnings Release: Here's Why Analysts Cut Their Osmotica Pharmaceuticals plc Price Target To US$8.50 Simply Wall St. +12.14%
Nov-14-19 04:05PM  Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results GlobeNewswire
Nov-08-19 01:00PM  Osmotica Pharmaceuticals plc to Provide Third Quarter 2019 Business and Financial Update on November 15, 2019 GlobeNewswire
Oct-28-19 03:50PM  Kaskela Law LLC Announces Investigation of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Investors ACCESSWIRE
Sep-27-19 06:50AM  Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors GlobeNewswire
Sep-18-19 06:50AM  Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid) GlobeNewswire
Sep-17-19 06:50AM  Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201 GlobeNewswire
Sep-04-19 06:50AM  Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting PR Newswire
Aug-28-19 04:30PM  Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference GlobeNewswire
Aug-22-19 01:06PM  Is Osmotica Pharmaceuticals (NASDAQ:OSMT) Using Debt Sensibly? Simply Wall St.
Aug-08-19 04:05PM  Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results GlobeNewswire
Aug-01-19 04:30PM  Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019 GlobeNewswire
Jul-02-19 09:03PM  Shareholder Rights Law Firm Johnson Fistel Launches Investigations PR Newswire
May-30-19 04:30PM  Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-23-19 12:05PM  Breakeven On The Horizon For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Simply Wall St. -8.46%
May-14-19 04:30PM  Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire -7.42%
May-09-19 04:01PM  Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire -5.14%
May-07-19 08:20AM  The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex Benzinga
May-06-19 04:30PM  Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (RVL) for Acquired Blepharoptosis (ptosis or droopy eyelid) GlobeNewswire
May-02-19 05:00PM  Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019 GlobeNewswire
Apr-12-19 12:45PM  Robbins Arroyo LLP is Investigating the Officers and Directors of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Shareholders Business Wire
Apr-11-19 12:05PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors Business Wire
Apr-08-19 03:06PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT) Business Wire
Apr-02-19 04:41PM  Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc. PR Newswire +5.19%
02:21PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT) Business Wire
Mar-29-19 02:17PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors Business Wire -9.89%
07:42AM  The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead Benzinga
Mar-28-19 11:54AM  SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC Business Wire -40.73%
Mar-27-19 04:05PM  Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire
Mar-13-19 07:07PM  Health Care Stocks Are Big Winners for an Aging Population GuruFocus.com
Dec-27-18 07:00AM  Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee GlobeNewswire -10.01%
Dec-03-18 04:30PM  Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire +12.06%
Nov-08-18 04:01PM  Osmotica Pharmaceuticals plc Reports Third Quarter 2018 Results GlobeNewswire
Nov-05-18 07:00AM  Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire
Oct-18-18 02:51PM  [$$] Osmotica Pharmaceuticals Shares Rise in Public Debut The Wall Street Journal
Oct-11-18 12:27PM  Osmotica's IPO: What You Need To Know Benzinga
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harsaul Foundation10% OwnerJan 13Buy5.001,250,0006,250,00022,485,297Jan 15 04:54 PM
Altchem Ltd10% OwnerJan 13Buy5.001,250,0006,250,00022,485,297Jan 15 04:39 PM
Venkataraman SriramDirectorJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:13 PM
Burgstahler David FDirectorJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:11 PM
Avista Capital Partners III GP10% OwnerJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:11 PM